Reference | </br>1:Specific binding of [3H]Ro 19-6327 (lazabemide) to monoamine oxidase B is increased in frontal cortex of suicide victims after controlling for age at death. Ballesteros J, Maeztu AI, Callado LF, Meana JJ, Gutiérrez M.Eur Neuropsychopharmacol. 2008 Jan;18(1):55-61. Epub 2007 Jun 13. PMID: 17570647 </br>2:Lazabemide, a selective, reversible monoamine oxidase B inhibitor, as an aid to smoking cessation. Berlin I, Aubin HJ, Pedarriosse AM, Rames A, Lancrenon S, Lagrue G; Lazabemide in Smoking Cessation Study Investigators..Addiction. 2002 Oct;97(10):1347-54. PMID: 12359039 </br>3:MAO-B inhibition by a single dose of l-deprenyl or lazabemide does not prevent neuronal damage following focal cerebral ischaemia in rats. Jolkkonen J, Kauppinen R, Nyman L, Haapalinna A, Sivenius J.Pharmacol Toxicol. 2000 Nov;87(5):242-5. PMID: 11129505 </br>4:Antioxidant activity of the monoamine oxidase B inhibitor lazabemide. Mason RP, Olmstead EG, Jacob RF.Biochem Pharmacol. 2000 Sep 1;60(5):709-16. PMID: 10927030 </br>5:Safety study of lazabemide (Ro19-6327), a new MAO-B inhibitor, on cardiac arrhythmias and blood pressure of patients with Parkinson/’s disease. Narabayashi H, Yamaguchi T, Sugi K, Mitamura H, Mizuno Y, Nakashima M.Clin Neuropharmacol. 1999 Nov-Dec;22(6):340-6. PMID: 10626094 </br>6:Lazabemide for the treatment of Alzheimer/’s disease: rationale and therapeutic perspectives. Cesura AM, Borroni E, Gottowik J, Kuhn C, Malherbe P, Martin J, Richards JG.Adv Neurol. 1999;80:521-8. Review. No abstract available. PMID: 10410766 </br>7:Pharmacokinetics and pharmacodynamics of single and multiple doses of the MAO-B inhibitor lazabemide in healthy subjects. Dingemanse J, Wood N, Jorga K, Kettler R.Br J Clin Pharmacol. 1997 Jan;43(1):41-7. PMID: 9056051 Free Article</br>8:Effect of lazabemide on the progression of disability in early Parkinson/’s disease. The Parkinson Study Group. [No authors listed]Ann Neurol. 1996 Jul;40(1):99-107. PMID: 8687199 </br>9:Tyramine pharmacodynamics during combined administration of lazabemide and moclobemide. Dingemanse J, Hussain Y, Korn A.Int J Clin Pharmacol Ther. 1996 Apr;34(4):172-7. PMID: 8861736 </br>10:Investigation on the structure of the active site of monoamine oxidase-B by affinity labeling with the selective inhibitor lazabemide and by site-directed mutagenesis. Cesura AM, Gottowik J, Lahm HW, Lang G, Imhof R, Malherbe P, Röthlisberger U, Da Prada M.Eur J Biochem. 1996 Mar 15;236(3):996-1002. PMID: 8665924 Free Article
|